Clinical trials: Prostate Disease
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Prostate Cancer
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
The purpose of this study is to investigate the effects of MK0822 in prolonging the time to first bone metastasis in men with castration-resistant prostate cancer.
- Trial name
- NCT00691899
- Testing
- odanacatib
- Sponsor
- Merck Sharp & Dohme LLC
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT03317392
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 22 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, MRI
MR-guided Focal Laser Ablation of the Prostate
Purpose of the investigators study is to determine the short and medium term histological cancer control of focal therapy using MR-guided focal laser ablation therapy in the treatment of localised prostate cancer.
- Conditions
- Prostate Cancer, MRI, Focal Laser Ablation
- Trial name
- NCT02200809
- Testing
- MR-guided focal laser ablation
- Where
- 3 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose…
- Trial name
- NCT03120832
- Testing
- PAN-301-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Prostate Cancer, Prostatic Adenocarcinoma
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Degarelix is an approved drug that is used to treat prostate cancer by lowering testosterone levels in the body. Degarelix is commonly given with radiation for prostate cancer, but less frequently with surgery since there has…
- Trial name
- NCT01542021
- Testing
- degarelix injection, androgen deprivation therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN)
o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer
Docetaxel is a standard chemotherapy for metastatic prostate cancer but is associated with dose-limiting peripheral neuropathy. Currently, no pharmacologic agents are established for prevention.
- Conditions
- Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neurotoxicity
- Trial name
- NCT07333976
- Testing
- Tadalafil 5 mg
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Prostate Cancer
ExosomeDx in MRI-negative Men With High PSA
Magnetic resonance imaging (MRI) has become the current standard of care in risk stratifying men with an elevated Prostate-specific antigen (PSA) to determine who needs to undergo prostate biopsy, which is invasive and carries a…
- Trial name
- NCT06966089
- Testing
- Urinary ExoDx test, Transrectal ultrasound-guided prostate biopsy, Transperineal 12-core prostate biopsy
- Where
- 6 sites in United States
- Volunteers
- 425 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer
The main objective of the phase I/II trial is to determine the safety and efficacy of a single fraction SBRT at a dose of 19 Gy in patients with localized prostate cancer.
- Trial name
- NCT03294889
- Testing
- Stereotactic body radition (SBRT)
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University Hospital, Geneva
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Research for the Efficacy and Safety of Percutaneous Tibial Nerve Stimulation to Promote Storage Symptoms Postoperative Recovery for Patients With Benign Prostatic Hyperplasia
The goal of this clinical trial is to guide and promote the clinical application of T-PTNS in promoting the postoperative recovery of urinary storage symptoms in patients with BPH.
- Trial name
- NCT06742489
- Testing
- Percutaneous tibial nerve stimulation device
- Volunteers
- 160 people
- Sponsor
- Zhu Yiping
Prostate Cancer
Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer
Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue.
- Trial name
- FLAME-PC (NCT07282808)
- Testing
- Molecular Evaluation for Risk of Recurrence after FT
- Where
- Singapore
- Volunteers
- 130 people
- Sponsor
- Singapore General Hospital
Prostatic Hyperplasia
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
This will be an open-label, three-period, fixed-sequence study to evaluate the drug-drug interaction, pharmacokinetics and safety of dutasteride and tamsulosin when administered alone and in-combination in Chinese healthy male…
- Trial name
- NCT01957189
- Testing
- Dutasteride and Tamsulosin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Genomics in Michigan Impacting Observation or Radiation
To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.
- Trial name
- G-MINOR (NCT02783950)
- Testing
- Decipher Prostate Cancer Classifier
- Where
- 13 sites in United States
- Volunteers
- 356 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Prostate Cancer Survey
There have been calls from patients, payers, healthcare providers, and policy makers for an evaluation of newer, high-cost radiation technologies compared to conventional forms of radiation therapy.
- Trial name
- NCT03128710
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue and may improve quality of life and help patients live more…
- Trial name
- NCT00067015
- Testing
- bicalutamide, goserelin acetate, assessment of therapy complications
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Prostate Cancer Utilities and Cost-Effectiveness Analysis
The purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. This research is being done because we do not know how patient preferences for health states related to prostate…
- Trial name
- NCT00203918
- Testing
- Survey, interview, patient utility scores (i.e. patient preference weights)
- Where
- United States
- Volunteers
- 481 people
- Sponsor
- University of Chicago
Benign Prostatic Hypertrophy
Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP
The purpose of this study is to compare two different types of scopes that can be used for HoLEP. HoLEP is performed through the urethra using a Laser scope to remove obstructing prostate tissue.
- Trial name
- NCT05308017
- Testing
- Richard Wolf 24F Laser scope, Karl Storz 28F Laser Scope
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Northwestern University
Prostate Cancer
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound (HIFU) or high dose rate (HDR) local therapy…
- Trial name
- NCT03949517
- Testing
- 68-Ga RM2, 68-Ga PSMA11, Investigational software and coils in PET/MR Scan
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Andrei Iagaru
Prostatic Neoplasms
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
The primary objective was to evaluate and compare the efficacy of androgen deprivation with or without docetaxel as determined by the median progression free survival (PFS) over the period of 18-month therapy and at least…
- Trial name
- Rising PSA (NCT00514917)
- Testing
- Docetaxel, Leuprolide, Bicalutamide
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.